Journal of Anesthesia & Pain Medicine(JAPM)
ISSN: 2474-9206 | DOI: 10.33140/JAPM
Impact Factor: 1.8*
Researchers and authors can directly submit their manuscript online through this link Online Manuscript Submission.
FDA Grants Breakthrough Device Designation to AutoGenomics INFINITI Neural Response Panel for the Identification of the Risk of Opioid Dependency
Abstract
Ramanath Vairavan
June 04, 2018 AutoGenomics, Inc., based in Carlsbad, CA, announced that its INFINITI® Neural Response Panel has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA).